rope01 rope02

Pipeline

Our internally developed pipeline of next-generation tyrosine kinase inhibitors (TKIs) target genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. We hold development and commercialization rights to our drug candidates in all regions except repotrectinib in certain countries in Greater China.

Discovery

Preclinical

Early Stage
Clinical Development

Late Stage
Clinical Development

Regulatory Submission

Repotrectinib (ROS1/TRK)¹

TRIDENT-1: Advanced NSCLC (ROS1) and solid tumors (NTRK)
Late Stage - Clinical Development
Pediatric advanced solid tumors
Late Stage - Clinical Development
TRIDENT-2: KRAS-targeting combination
Preclinical

TPX-0022 (MET)¹

SHIELD-1: Advanced solid tumors
Early Stage - Clinical Development

SHIELD-2: EGFR combination
Preclinical

TPX-0046 (RET)²

Advanced solid tumors
Early Stage - Clinical Development

TPX-0131 (ALK)²

Advanced NSCLC
Preclinical

Discovery Programs

Multiple Oncology Targets
Discovery

¹ Partnered with Zai Lab in Greater China; Turning Point retains worldwide rights outside of Greater China. ² Turning Point retains worldwide rights.

Turning Point Therapeutics has been granted Breakthrough Therapy designation by the Food and Drug administration (FDA) for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have not been treated with a ROS1 tyrosine kinase inhibitor (TKI-naïve). Repotrectinib has also been granted three Fast Track designations by the FDA in ROS1-positive NSCLC patients who are TKI-naïve, ROS1-positive NSCLC patients who have been previously treated with one prior platinum chemotherapy and one prior ROS1 TKI, and NTRK-positive patients with advanced solid tumors who have progressed following treatment with at least one prior line of chemotherapy and one or two prior TRK TKIs.